ClinicalTrials.Veeva

Menu

Lung Bacteriobiota and Influenza Mortality (MicroFlu)

U

University of Bordeaux

Status

Unknown

Conditions

Influenza
Critical Illness

Treatments

Diagnostic Test: influenza screening

Study type

Observational

Funder types

Other

Identifiers

NCT04131296
MicroFlu

Details and patient eligibility

About

Influenza is a potentially lethal disease still responsible for thousands excess deaths both in Europe and the United States. Despite the use of neuraminidase inhibitors, its treatment is mostly based on symptomatic care. Lung microbiota has been shown to be involved in the immunity against influenza and is correlated with lung inflammation in numerous chronic respiratory diseases. We therefore aim to analyse the correlation between lung bacteriobiota and influenza ICU mortality

Full description

Influenza is a viral disease which is still responsible for thousands of excess deaths par year both in Europe and in the US. Despite the use of neuraminidase inhibitors, its treatment is mostly based on symptomatic care. As lung microbiota is correlated with lung inflammation in numerous chronic respiratory diseases, we hypothesize that lung microbiota would be correlated with influenza outcomes. In a pilot study, we found that lung bacteriobiota but not mycobiota is associated with influenza ICU mortality. We therefore aim to confirm this correlation between lung bacteriobiota and influenza mortality.

Enrollment

64 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patient above 18 year-old admitted to intensive care unit
  • Influenza diagnosis by PCR or rapid diagnostic test

Exclusion criteria

  • Guardianship or curatorship
  • Prisoners
  • No health insurance
  • No legal representative

Trial contacts and locations

3

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems